As of close of business last night, Macrogenics Inc’s stock clocked out at $18.10, down -1.36% from its previous closing price of $18.35. In other words, the price has decreased by -$0.25 from its previous closing price. On the day, 1588530 shares were traded.
Ratios:
To gain a deeper understanding of MGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
On March 04, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $12 to $24.
H.C. Wainwright Downgraded its Buy to Neutral on February 14, 2024, whereas the target price for the stock was revised from $12 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 04 ’24 when Peters Jeffrey Stuart sold 51,395 shares for $15.55 per share. The transaction valued at 799,148 led to the insider holds 0 shares of the business.
Peters Jeffrey Stuart sold 19,625 shares of MGNX for $421,938 on Mar 06 ’24. The Senior VP and General Counsel now owns 8,895 shares after completing the transaction at $21.50 per share. On Mar 04 ’24, another insider, Risser Eric Blasius, who serves as the Chief Operating Officer of the company, sold 41,159 shares for $19.76 each. As a result, the insider received 813,501 and left with 38,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 1.13B and an Enterprise Value of 937.76M. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.23 while its Price-to-Book (P/B) ratio in mrq is 7.36. Its current Enterprise Value per Revenue stands at 16.40 whereas that against EBITDA is 464.93.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $21.88, while it has fallen to a 52-week low of $4.29. The 50-Day Moving Average of the stock is 16.73, while the 200-Day Moving Average is calculated to be 9.08.
Shares Statistics:
It appears that MGNX traded 1.59M shares on average per day over the past three months and 1.96M shares per day over the past ten days. A total of 62.07M shares are outstanding, with a floating share count of 58.56M. Insiders hold about 6.21% of the company’s shares, while institutions hold 95.44% stake in the company. Shares short for MGNX as of Mar 15, 2024 were 5.6M with a Short Ratio of 3.53, compared to 6.38M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.97% and a Short% of Float of 10.94%.
Earnings Estimates
As of right now, 10 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.64 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.79, while EPS last year was -$0.61. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.42 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$1.76 and -$3.19 for the fiscal current year, implying an average EPS of -$2.55. EPS for the following year is -$1.02, with 7 analysts recommending between $3.35 and -$2.76.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $15.66M. It ranges from a high estimate of $30M to a low estimate of $8.92M. As of the current estimate, Macrogenics Inc’s year-ago sales were $24.5M, an estimated decrease of -36.10% from the year-ago figure.
A total of 10 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $125.7M, while the lowest revenue estimate was $35.9M, resulting in an average revenue estimate of $66.79M. In the same quarter a year ago, actual revenue was $58.75M, up 13.70% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $133.7M in the next fiscal year. The high estimate is $326.22M and the low estimate is $33.3M. The average revenue growth estimate for next year is up 100.20% from the average revenue estimate for this year.
